CTLA4 and neoplasm: Studies have shown that the highly expressed coinhibitory molecule CTLA-4 on Tregs competes with CD28 on Teff cells to attach to CD80/86 on the surface of APCs, resulting in the inhibition of Teffs and APCs activation and increased apoptosis, thereby weakening the immune killing effect of Teffs on tumor cells [36].